Q-omics provides the consensus-scored TMEM79 profile across patient tissues and cancer cell-line models. TMEM79 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM79 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, TMEM79 RNA expression shows 19,466 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where TMEM79 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM79 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM79 survival associations across molecular data types. TMEM79 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM79 RNA expression–survival associations across cancer types. High TMEM79 expression shows unfavorable associations in KIRC, ACC, LIHC, LGG, KIRP and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM79 RNA expression.
This table summarizes TMEM79 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM79. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM79 shows higher tumor expression in THCA, KIRP, KIRC, COAD, LUAD and LIHC. The THCA box plot shows higher TMEM79 RNA expression in tumor versus normal tissue (log2 FC = +1.834, t-test p < 0.001).
This table shows molecular features associated with TMEM79 in patient tissues and cancer cell lines. In patient samples, TMEM79 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM79 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
